跳至主要内容
临床试验/NCT07144085
NCT07144085尚未招募1 期

Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases.

Yi Tian1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2025年9月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
尚未招募
发起方
入组人数
80
试验地点
1
主要终点
Count of participants with treatment-emergent adverse events

研究概览

简要总结

A new radiotracer, 68Ga-FXX489 (NNS309), has been developed for tracking fibroblast activation protein (FAP) and visualizing the tumor stroma. The purpose of the study is to explore the diagnostic value of 68Ga-FXX489 (NNS309) PET/CT imaging in oncological diseases, to assess its safety, imaging characteristics, and biodistribution after administration.

详细描述

Initially the investigator(s) will focus on imaging pancreatic cancer, lung cancer, breast cancer, gastric cancer, colorectal cancer.

STUDY AIMS

  1. Determine the dosimetry for gallium-68 labelled 68Ga- FXX489(NNS309).
  2. Evaluate the uptake and retention of radiotracer in a variety of solid tumors with 68Ga- FXX489(NNS309).
  3. Evaluate the ability of FAP-2286 to detect metastatic disease. PRIMARY OBJECTIVES

1.Safety of 68Ga- FXX489(NNS309). 2.determine the organ dosimetry of 68Ga- FXX489(NNS309). 3.To assess the feasibility of detecting tumor uptake using FXX489(NNS309). 4.To determine the feasibility of detecting metastatic disease using FXX489(NNS309).

EXPLORATORY OBJECTIVES

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with a high suspicion of oncological diseases.
  • Age: 18-80 years, no gender restriction, able to express themselves independently, and willing to participate in this study with a signed informed consent form.

排除标准

  • Failure to sign the informed consent form.
  • Severe visual or auditory impairment, cognitive disorders, or patients with claustrophobia who cannot communicate effectively.
  • Severe cardiac dysfunction, cardiac function class III-IV.
  • Renal failure (serum creatinine level > 1.2 mg/dl).
  • Allergy to alcohol.
  • Use of drugs within 1 week prior to the examination that can cause a disulfiram-like reaction with alcohol, such as penicillins, cephalosporins, or cefotetan.
  • Known pregnancy.

研究组 & 干预措施

Tumor population

Experimental

PET imaging will begin 30 +/-10 minutes, 60 +/-15 minutes and 120 +/-20 minutes after injection of 68Ga-FXX489 or 68Ga-FAP-2286 or 18F-FDG.

干预措施: 68Ga-FXX489 (Drug)

Tumor population

Experimental

PET imaging will begin 30 +/-10 minutes, 60 +/-15 minutes and 120 +/-20 minutes after injection of 68Ga-FXX489 or 68Ga-FAP-2286 or 18F-FDG.

干预措施: Positron Emission Tomography (PET) imaging (Procedure)

Tumor population

Experimental

PET imaging will begin 30 +/-10 minutes, 60 +/-15 minutes and 120 +/-20 minutes after injection of 68Ga-FXX489 or 68Ga-FAP-2286 or 18F-FDG.

干预措施: Gallium-68 labelled (68Ga-) FAP-2286 (Drug)

结局指标

主要结局

Count of participants with treatment-emergent adverse events

时间窗: Up to 3 days

The frequency and severity of treatment emergent adverse events following FXX489(NNS306) injection will be descriptively reported as classified and graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0

Proportion of radiation-absorbed doses of radiolabeled FAP-2286.

时间窗: Up to 3 days

Volumes of interest of 68Ga- will be drawn around regions identified on the scans, including the liver, spleen, kidneys, urinary bladder, the central sacrum (for hematopoietic marrow) and whole body. Data will be fitted using the Simulation, Analysis, and Modeling Software II (SAAM II) software. Time integrals of activity will be entered into the Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA/EXM) software, using the reference adult model. The results from all patients enrolled will be combined to allow the calculation of mean, standard deviation (SD), and range of radiation-absorbed doses to individual organs

Standardized Uptake Values (SUVs)

时间窗: Up to 3 days

The maximum Standardized Uptake Value (SUVmax) will be calculated for up to five lesions in each patient, with mediastinal blood pool being used as background activity.

Tumor-to-background (TBR) Ratio

时间窗: Up to 3 days

TBR ratios will be calculated for up to five lesions in each patient, with mediastinal blood pool being used as background activity. The median and range of the measured TBRs will be reported across all RECIST measurable lesions as a table broken down by location (organ metastases, nodal metastases and bone metastases).

Proportion of positive lesions on FXX489(NNS306) PET

时间窗: Up to 3 days

Conventional imaging will be reviewed in conjunction with the FXX489(NNS306) PET images. Lesions will be characterized as positive on FXX489(NNS306) PET if uptake is greater than 1.5 times higher than mediastinal blood pool and uptake cannot be attributed to physiologic or inflammatory reasons. Conventional imaging will be interpreted as positive by each lesion if the short axis dimension of lymph nodes is greater than 1 centimeter (cm), and organ metastases measure greater than 1 cm in long axis. The gold standard will be the combination of conventional imaging and FXX489(NNS306) PET in combination with clinical follow-up and histopathology (if available). The number of lesions detected by each modality will be compared and sensitivity will be computed. Since this is a proof-of-concept study, it is not powered for the test of agreement. Nevertheless, the agreement will be tested using McNemar's test.

次要结局

未报告次要终点

研究者

发起方
Yi Tian
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Yi Tian

The Master's Degree Candidate of the Department of Nuclear Medicine, The First Affiliated Hospital of China Medical University

First Hospital of China Medical University

研究点 (1)

Loading locations...

相似试验